Delaware Diagnostic Labs, LLC

Delaware Diagnostic Labs, LLC was paid $8.53M by Medicaid between May 2018 and Dec 2024, across 55 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 49% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Delaware

Rank by total paid#2 of 11

Median peer was paid$134K

This provider vs. median64×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	1,270	$129K
2019	3,010	$286K
2020	13,802	$608K
2021	93,847	$2.63M
2022	93,622	$2.44M
2023	35,487	$1.36M
2024incomplete	24,245	$1.09M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	49%	85,858	46,156	$4.15M
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	27%	19,364	16,409	$2.32M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	4.5%	53,211	22,220	$386K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	4.3%	59,601	26,459	$368K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	3.7%	3,108	2,515	$317K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	3.4%	3,436	2,380	$289K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	2.1%	2,297	2,038	$177K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	1.9%	3,909	3,423	$159K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	1.2%	3,389	2,894	$101K
87186		<1%	2,614	2,149	$53K
87481		<1%	2,696	2,221	$49K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	2,028	969	$43K

43 more codes

87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	327	$41K
87640		<1%	3,085	$20K
87653		<1%	3,087	$20K
86409		<1%	687	$9K
86328		<1%	1,642	$8K
81002		<1%	4,902	$3K
80061	Lipid panel	<1%	947	$2K
83036	Hemoglobin; glycosylated (A1C)	<1%	661	$1K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	863	$1K
84443	Thyroid stimulating hormone (TSH)	<1%	521	$1K
80053	Comprehensive metabolic panel	<1%	667	$968.50
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	125	$864.49
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	96	$857.60
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	99	$857.60
36415	Collection of venous blood by venipuncture	<1%	2,164	$735.39
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	331	$725.08
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	299	$718.20
87541		<1%	299	$718.20
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	89	$627.39
87641		<1%	334	$536.61
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	165	$436.13
86803		<1%	184	$252.12
86038		<1%	200	$179.40
80048	Basic metabolic panel (calcium, ionized)	<1%	252	$179.38
80076		<1%	211	$146.32
86431		<1%	203	$81.00
84436		<1%	130	$66.67
86140		<1%	204	$63.00
85610		<1%	98	$54.00
86704		<1%	80	$50.29
81001		<1%	54	$43.50
87340		<1%	80	$36.96
86706		<1%	80	$35.85
86708		<1%	80	$34.07
85027		<1%	69	$31.33
84479		<1%	80	$28.00
85730		<1%	80	$27.00
84439		<1%	67	$16.85
83655		<1%	14	$11.87
86592		<1%	14	$7.54
P9603	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled	<1%	155	$1.00
87486		0%	12	$0.00
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	0%	35	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialWANG, BO (LAB DIRECTOR)